Table 3.

Repeated measures logistic regression of cardiovascular risk scores with frailty in MACS men ^a,b,c

	HIV− (n=17,349 study visits; 1,518 frail visits)			HIV+ (n=17,771 study visits, 2,138 frail visits)
	OR	95% CI	P a	OR	95% CI	P a
Cardiovascular risk scores, continuous
ATP-III FRS, % (unadjusted)	1.05	1.04, 1.06	<0.001	1.04	1.03, 1.05	<0.001
ATP-III FRS, % (adjusted)	1.05	1.04, 1.06	<0.001	1.04	1.03, 1.05	<0.001
ACC/AHA PCE, % (unadjusted)	1.04	1.04, 1.05	<0.001	1.03	1.03, 1.04	<0.001
ACC/AHA PCE, % (adjusted)	1.04	1.03, 1.05	<0.001	1.03	1.02, 1.04	<0.001
Cardiovascular risk scores, strata
ATP-III FRS, %
Low risk (<10%)	Ref			Ref
Moderate risk (10–20%) (unadjusted)	1.53	1.35, 1.75	<0.001	1.30	1.15, 1.47	<0.001
Moderate risk (10–20%) (adjusted)	1.54	1.34, 1.77	<0.001	1.29	1.14, 1.47	<0.001
High risk (>20%) (unadjusted)	2.33	1.75, 3.10	<0.001	2.00	1.58, 2.53	<0.001
High risk (>20%) (adjusted)	2.31	1.74, 3.07	<0.001	2.03	1.60, 2.58	<0.001
ACC/AHA PCE, %
Low risk (<7.5%)	Ref			Ref
High risk (≥7.5%) (unadjusted)	2.02	1.74, 2.34	<0.001	1.44	1.27, 1.63	<0.001
High risk (≥7.5%) (adjusted)d	1.98	1.68, 2.34	<0.001	1.44	1.26, 1.64	<0.001

ACC/AHA PCE: American College of Cardiology/American Heart Association pooled cohort equations; ATP-III FRS: Adult Treatment Program III Framingham risk score; CI: confidence interval; HIV: human immunodeficiency virus; MACS: Multicenter AIDS Cohort Study; OR: odds ratio;

^aAdjusted analyses include as covariates: education, income, cholesterol medication use, HCV serostatus, and in HIV+ participants, CD4 count, ART therapy and suppressed HIV viral load

^bATP-III FRS and ACC/AHA PCE are in men 20–79 and 40–79 years of age, respectively

^cACC/AHA PCE were available for 15,681 (90%) HIV− and 15,394 (87%) HIV+ study visits

^dP_Interaction = 0.003 by HIV serostatus